JPS60224632A - External drug for treating dermatopathy - Google Patents

Abstract

PURPOSE:The titled external drug containing kallikrein. CONSTITUTION:An external drug for treating dermatopathy obtained by kneading kallikrein simply with a base, e.g. water-absorbing ointment, white ointment, hydrophilic ointment, simple ointment or hydrophilic vaseline, or if necessary dissolving the kallikrein in propylene glycol or polyethylene glycol (preferably 2- 10% based on the base), and kneading the resultant solution in the base. The content of the kallikrein therein is preferably 1-100g kallikrein units/g, particularly preferably 10-30g kallikrein units/g. The drug is effective particularly for dermatopathy, e.g. chaps, hand roughening, dermatitis, necrotic angiopathy, frostbite and bed sore. The kallikrein is widely used as a vasodilator, and regarded as effective for cerebral arteriosclerosis, hypertension and tissue trophopathy derived from hematogenic disorder. The kallikrein is wholly used in the form of tablet or injection, and there has been no external drug in the past.

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an external preparation for treating skin diseases containing kallikrein.

Kallikrein is a substance secreted by the pancreas, and is an enzyme that releases kinin from plasma proteins and induces a blood pressure-lowering effect. This product was first extracted from crushed dog viscera, but has since been extracted from various animals including humans. Similar substances are obtained from body fluids and tissues.

In 1978, the entire amino acid sequence of kallikrein derived from pig pancreas was determined, and its pharmacological effects were also detailed in JI.
K studied O That is, kallikrein breaks down kininogen in the blood.

Using dogs, it was shown that the liberated kallidin acts directly on vascular smooth muscle without going through nerves, dilating peripheral blood vessels, decreasing vascular resistance, increasing blood flow, and lowering blood pressure. This was confirmed by several pharmacological experiments.

Today, kallikrein is widely used as a vasodilator and is said to be effective for cerebral arteriosclerosis, hypertension, and tissue malnutrition caused by blood circulation disorders.

However, all kallikrein preparations currently on the market are used in the form of tablets and injections, and there are no external preparations available.

The reason for this is that kallikrein is unstable in water.

This is also due to the fact that research into kallikrein for skin diseases has not progressed.

The present inventor conducted extensive research to develop a new use for kallikrein using a new dosage form, and found that kallikrein has a high affinity with the ointment base, and that kallikrein ointment, which has a 1 cFi content, is currently used in the treatment of skin diseases. The present invention was completed by discovering that this is suitable.

In the present invention, kallikrein derived from body fluids and organs of various animals can be used for #-, but it is usually preferable to use #4 derived from pig pancreas because it is easily available.

In the present invention, these kallikrein are blended into an ointment base. Examples of bases that can be used include, for example, water-absorbing ointment, white ointment, hydrophilic ointment, simple ointment, and hydrophilic petrolatum of the Japanese Pharmacopoeia.

All other conventional ointment bases may be used as appropriate.

Kallikrein and the base may be blended by simply kneading the two, and if necessary, it is also advantageous to dissolve the kallikrein in propylene glycol or polyethylene glycol and then incorporate it into the base VclII. The ratio of these organic solvents to the base may be arbitrary, but is preferably 2 to 10 ctH1I, and <= about 4 ctH1I. In this manner, the external preparation for treating skin diseases of the present invention can be produced. The kallikrein content therein is arbitrary, but preferably 1 to 100 kallikrein units/
g, preferably 10 to 30 force recline units/4I
It is g.

When the kallikrein-containing external preparation Fi of the present invention obtained by the above-mentioned combination was used for various skin diseases, it showed the following excellent effects.

As explained in detail above, the kallikrein-containing external preparation of the present invention is a new dosage form that has never been used before.

Moreover, the Kallikrein recovery agent thus obtained shows a remarkable therapeutic effect when applied to areas of skin diseases that no one has tried before.Therefore, the present invention can be truly called a novel and useful invention. .

An example of the method for producing the external preparation of the present invention is shown below for reference. Of course, this is merely an example for reference, and the present invention is not limited thereby.

Take purified pig liver-derived kallikrein, dissolve it in an appropriate amount of propylene glycol, then add the above solution to hydrophilic petrolatum of the Japanese Pharmacopoeia so that the concentration is 4% (v/w) K, and mix thoroughly to determine the kallikrein concentration. The Icv was adjusted to 4 to give a concentration of 27 Recrein units/g to obtain the desired cream-like ointment preparation.

Patent applicant Shun Naito - Procedural amendment (method) 1. Indication of the case Japanese Patent Application No. 59-82476 2. Title of the invention External preparation for the treatment of skin diseases 3. Relationship with the person making the amendment Patent applicant Address: 37 Kitakayama Kawaramachi, Yamashina-ku, Kyoto City? 7 July 31, 1982 (shipping date) 5. Application subject to amendment and specification 6. Contents of amendment as attached.

Claims (1)

[Scope of Claims] 1. External preparation for treating skin diseases comprising kallikrein 2. External preparation for treating skin diseases according to claim 1 comprising kallikrein and an ointment base 3. Roughness, dermatitis, necrotizing vasculitis. External preparation for treating the skin disease described in item 1, which is chilblains and bedsores.